Please enable JavaScript to continue using this application.

Compare $KLRS vs $SER | Chartloom

Compare

$KLRS vs $SER

Kalaris Therapeutics Inc · Serina Therapeutics Inc

KLRS

Kalaris Therapeutics Inc

SER

Serina Therapeutics Inc

Compare $KLRS vs $SER

Comparing Kalaris Therapeutics Inc and Serina Therapeutics Inc

KLRSKalaris Therapeutics Inc

SERSerina Therapeutics Inc

KLRSKalaris Therapeutics Inc

Market cap

$56M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-71.6%

52W performance

-64.2%

FCF yield

-73.4%

SERSerina Therapeutics Inc

Market cap

$30M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-3.8%

52W performance

-64.5%

FCF yield

-70.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

KLRS

SER

Detailed metrics comparison

KLRS

Kalaris Therapeutics Inc

SER

Serina Therapeutics Inc

Market Cap

KLRS$56M

SER$30M

Enterprise Value

KLRS$45M

SER$10M

Price

KLRS$2.36

SER$2.00

P/E Ratio

KLRSN/A

SERN/A

P/S Ratio

KLRS0.00x

SER345.73x

EV/Sales

KLRS0.00x

SER207.28x

EV/EBITDA

KLRS0.00x

SER0.00x

P/B Ratio

KLRS1.02x

SER2.66x

P/FCF Ratio

KLRSN/A

SERN/A

EV/FCF

KLRS-1.09x

SER-0.47x

PEG Ratio

KLRSN/A

SERN/A

Forward P/E (NTM)

KLRSN/A

SERN/A

Forward P/S (NTM)

KLRSN/A

SERN/A

Revenue (TTM)

KLRS$0

SER$0

Revenue Growth (YoY)

KLRSN/A

SERN/A

Forward Rev Growth

KLRS180.3%

SER0.0%

Gross Margin (TTM)

KLRS0.0%

SER65.1%

Operating Margin (TTM)

KLRS0.0%

SER0.0%

EBITDA Margin (TTM)

KLRS0.0%

SER0.0%

Net Margin (TTM)

KLRS0.0%

SER0.0%

FCF Margin (TTM)

KLRSN/A

SERN/A

Net Income (TTM)

KLRS$-44M

SER$-17M

FCF (TTM)

KLRS$-41M

SER$-21M

EPS (TTM)

KLRS-$1.86

SER-$1.03

ROE (TTM)

KLRS-7171.0%

SER-10679.0%

ROA (TTM)

KLRS-4295.0%

SER-9480.0%

ROIC (TTM)

KLRS-4719.0%

SER-8268.0%

Cash

KLRS$43M

SER$23M

Debt

KLRS$32M

SER$3M

Net Cash/Debt

KLRS$11M

SER$20M

Current Ratio (TTM)

KLRS10.98x

SER6.65x

Quick Ratio (TTM)

KLRS10.76x

SER6.12x

Debt/Equity (TTM)

KLRS0.56x

SER0.16x

Debt/Assets (TTM)

KLRS0.0%

SER0.0%

Interest Coverage (TTM)

KLRSN/A

SERN/A

Net Debt/EBITDA (TTM)

KLRS0.00x

SER0.00x

Beta

KLRS0.44

SER8.13

52W Performance

KLRS-64.2%

SER-64.5%

YTD Performance

KLRS-71.6%

SER-3.8%

% from 52W High

KLRS-80.1%

SER-65.0%

% from 52W Low

KLRS0.4%

SER63.9%

Asset Turnover (TTM)

KLRS0.00x

SER0.02x

FCF Yield (TTM)

KLRS-73.4%

SER-70.7%

Earnings Yield (TTM)

KLRS-78.8%

SER-56.2%

Dividend Yield (TTM)

KLRSN/A

SERN/A

Rule of 40

KLRS0.0

SER0.0

EV/GP/RG

KLRSN/A

SERN/A

Ticker research

View KLRS research View SER research

Metric	KLRS Kalaris Therapeutics Inc	SER Serina Therapeutics Inc
Market & Valuation
Market Cap	$56M	$30M
Enterprise Value	$45M	$10M
Price	$2.36	$2.00
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	345.73x
EV/Sales	0.00x	207.28x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.02x	2.66x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.09x	-0.47x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	180.3%	0.0%
Profitability
Gross Margin (TTM)	0.0%	65.1%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-44M	$-17M
FCF (TTM)	$-41M	$-21M
EPS (TTM)	-$1.86	-$1.03
ROE (TTM)	-7171.0%	-10679.0%
ROA (TTM)	-4295.0%	-9480.0%
ROIC (TTM)	-4719.0%	-8268.0%
Financial Health
Cash	$43M	$23M
Debt	$32M	$3M
Net Cash/Debt	$11M	$20M
Current Ratio (TTM)	10.98x	6.65x
Quick Ratio (TTM)	10.76x	6.12x
Debt/Equity (TTM)	0.56x	0.16x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.44	8.13
52W Performance	-64.2%	-64.5%
YTD Performance	-71.6%	-3.8%
% from 52W High	-80.1%	-65.0%
% from 52W Low	0.4%	63.9%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.02x
FCF Yield (TTM)	-73.4%	-70.7%
Earnings Yield (TTM)	-78.8%	-56.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View KLRS research	View SER research

Valuation

P/S Ratio

KLRS

0.00x

SER

345.73x

EV/FCF

KLRS

-1.09x

SER

-0.47x

Growth & revenue

Forward Revenue Growth

KLRS

180.3%

SER

0.0%

Profitability & performance

Gross Margin

SER

65.1%

KLRS

0.0%

ROE

KLRS

-7171.0%

SER

-10679.0%

FCF Yield %

SER

-70.7%

KLRS

-73.4%

52-Week Performance

KLRS

-64.2%

SER

-64.5%

Detailed metrics comparison

KLRS

Kalaris Therapeutics Inc

SER

Serina Therapeutics Inc

Market Cap

KLRS$56M

SER$30M

Enterprise Value

KLRS$45M

SER$10M

Price

KLRS$2.36

SER$2.00

P/E Ratio

KLRSN/A

SERN/A

P/S Ratio

KLRS0.00x

SER345.73x

EV/Sales

KLRS0.00x

SER207.28x

EV/EBITDA

KLRS0.00x

SER0.00x

P/B Ratio

KLRS1.02x

SER2.66x

P/FCF Ratio

KLRSN/A

SERN/A

EV/FCF

KLRS-1.09x

SER-0.47x

PEG Ratio

KLRSN/A

SERN/A

Forward P/E (NTM)

KLRSN/A

SERN/A

Forward P/S (NTM)

KLRSN/A

SERN/A

Revenue (TTM)

KLRS$0

SER$0

Revenue Growth (YoY)

KLRSN/A

SERN/A

Forward Rev Growth

KLRS180.3%

SER0.0%

Gross Margin (TTM)

KLRS0.0%

SER65.1%

Operating Margin (TTM)

KLRS0.0%

SER0.0%

EBITDA Margin (TTM)

KLRS0.0%

SER0.0%

Net Margin (TTM)

KLRS0.0%

SER0.0%

FCF Margin (TTM)

KLRSN/A

SERN/A

Net Income (TTM)

KLRS$-44M

SER$-17M

FCF (TTM)

KLRS$-41M

SER$-21M

EPS (TTM)

KLRS-$1.86

SER-$1.03

ROE (TTM)

KLRS-7171.0%

SER-10679.0%

ROA (TTM)

KLRS-4295.0%

SER-9480.0%

ROIC (TTM)

KLRS-4719.0%

SER-8268.0%

Cash

KLRS$43M

SER$23M

Debt

KLRS$32M

SER$3M

Net Cash/Debt

KLRS$11M

SER$20M

Current Ratio (TTM)

KLRS10.98x

SER6.65x

Quick Ratio (TTM)

KLRS10.76x

SER6.12x

Debt/Equity (TTM)

KLRS0.56x

SER0.16x

Debt/Assets (TTM)

KLRS0.0%

SER0.0%

Interest Coverage (TTM)

KLRSN/A

SERN/A

Net Debt/EBITDA (TTM)

KLRS0.00x

SER0.00x

Beta

KLRS0.44

SER8.13

52W Performance

KLRS-64.2%

SER-64.5%

YTD Performance

KLRS-71.6%

SER-3.8%

% from 52W High

KLRS-80.1%

SER-65.0%

% from 52W Low

KLRS0.4%

SER63.9%

Asset Turnover (TTM)

KLRS0.00x

SER0.02x

FCF Yield (TTM)

KLRS-73.4%

SER-70.7%

Earnings Yield (TTM)

KLRS-78.8%

SER-56.2%

Dividend Yield (TTM)

KLRSN/A

SERN/A

Rule of 40

KLRS0.0

SER0.0

EV/GP/RG

KLRSN/A

SERN/A

Ticker research

View KLRS research View SER research

Metric	KLRS Kalaris Therapeutics Inc	SER Serina Therapeutics Inc
Market & Valuation
Market Cap	$56M	$30M
Enterprise Value	$45M	$10M
Price	$2.36	$2.00
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	345.73x
EV/Sales	0.00x	207.28x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.02x	2.66x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.09x	-0.47x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	180.3%	0.0%
Profitability
Gross Margin (TTM)	0.0%	65.1%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-44M	$-17M
FCF (TTM)	$-41M	$-21M
EPS (TTM)	-$1.86	-$1.03
ROE (TTM)	-7171.0%	-10679.0%
ROA (TTM)	-4295.0%	-9480.0%
ROIC (TTM)	-4719.0%	-8268.0%
Financial Health
Cash	$43M	$23M
Debt	$32M	$3M
Net Cash/Debt	$11M	$20M
Current Ratio (TTM)	10.98x	6.65x
Quick Ratio (TTM)	10.76x	6.12x
Debt/Equity (TTM)	0.56x	0.16x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.44	8.13
52W Performance	-64.2%	-64.5%
YTD Performance	-71.6%	-3.8%
% from 52W High	-80.1%	-65.0%
% from 52W Low	0.4%	63.9%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.02x
FCF Yield (TTM)	-73.4%	-70.7%
Earnings Yield (TTM)	-78.8%	-56.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View KLRS research	View SER research